Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Generated: July 21, 2019

DrugPatentWatch Database Preview

Patent: 9,694,088

Try a free trial See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,694,088

Title:	Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Abstract:	Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.
Inventor(s):	Govindan; Serengulam V. (Summit, NJ), McBride; William J. (Boonton, NJ), Sathyanarayan; Nalini (Edison, NJ), Mazza-Ferreira; Christine (Park Ridge, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	15/270,542
Patent Claims:	see list of patent claims

Details for Patent 9,694,088

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Bristol Myers Squibb	OPDIVO	nivolumab	INJECTABLE;INJECTION	125554	001	2015-11-23	➤ Sign Up	Immunomedics, Inc. (Morris Plains, NJ)	➤ Sign Up	RX	Orphan	search
Bristol Myers Squibb	OPDIVO	nivolumab	INJECTABLE;INJECTION	125527	002	2015-03-04	➤ Sign Up	Immunomedics, Inc. (Morris Plains, NJ)	➤ Sign Up	RX		search
Bristol Myers Squibb	OPDIVO	nivolumab	INJECTABLE;INJECTION	125527	001	2015-03-04	➤ Sign Up	Immunomedics, Inc. (Morris Plains, NJ)	➤ Sign Up	RX		search
Nps Pharms Inc	NATPARA	parathyroid hormone	INJECTABLE;INJECTION	125511	004	2015-01-23	➤ Sign Up	Immunomedics, Inc. (Morris Plains, NJ)	➤ Sign Up	RX	Orphan	search
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source

International Patent Family for US Patent 9,694,088

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Publication Date
World Intellectual Property Organization (WIPO)	2014124227	Aug 14, 2014
United States of America	2014219956	Aug 07, 2014
United States of America	2015018516	Jan 15, 2015
United States of America	2015283264	Oct 08, 2015
Country	Patent Number	Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.